Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s First HIV Vaccine Enters Phase II Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA approved an application March 23 for an HIV vaccine funded by the Chinese government and developed by Jilin University to proceed to Phase II clinical trials. The trials will enroll 230 healthy people with high risk of HIV infection. The vaccine targets an HIV subtype that was detected in Chinese patients

You may also be interested in...



Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval

SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News

Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval

SHANGHAI - China's State FDA held a pre-IND meeting June 17 with Shanghai-based Hutchison MediPharma on its Phase I development plan for its solid tumor drug HMPL-012, the company told PharmAsia News

AIDS Was Top Killer In China Among Infectious Diseases In 2008, Says Ministry Of Health

SHANGHAI - AIDS became the leading cause of death in China among all infectious diseases in 2008, and claimed 6,897 lives in the first nine months of last year, according to a report issued on the Chinese Ministry of Health's official Web site

Latest News
UsernamePublicRestriction

Register

SC071180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel